Neurocrine execs shrug off a PhII setback for Tourette syndrome
Neurocrine was forced to concede that its lead drug – already on track at the FDA with an application for tardive dyskinesia — just flunked a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
